Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral tacrolimus pilot study in hereditary hemorrhagic telangiectasia with severe bleeding
NL-OMON48255Phase 2Active, not recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Mar 2020
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacrolimus in hereditary hemorrhagic telangiectasia (HHT), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Change in hemoglobin level. Started Mar 2020; status: active, not recruiting.
02
Drugs
tacrolimus
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NL-OMON48255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48255.